These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34703742)

  • 1. One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab.
    Abouhussein MA; Gomaa AR
    Taiwan J Ophthalmol; 2021; 11(3):266-272. PubMed ID: 34703742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.
    Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
    Salimi A; Vila N; Modabber M; Kapusta M
    Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis.
    Pessoa B; Malheiro L; Carneiro I; Monteiro S; Coelho J; Coelho C; Figueira J; Meireles A; Melo Beirão JN
    Clin Ophthalmol; 2021; 15():253-260. PubMed ID: 33519187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs.
    Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH
    Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema.
    Klein KA; Cleary TS; Reichel E
    Int J Retina Vitreous; 2017; 3():16. PubMed ID: 28373914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of the efficacy of early switching from bevacizumab to aflibercept or ranibizumab in diabetic macular edema.
    Ataş M; Ozsaygılı C; Bayram N; Unal S
    Eur J Ophthalmol; 2022 Nov; ():11206721221137164. PubMed ID: 36330651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
    Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab.
    Lim LS; Ng WY; Mathur R; Wong D; Wong EY; Yeo I; Cheung CM; Lee SY; Wong TY; Papakostas TD; Kim LA
    Clin Ophthalmol; 2015; 9():1715-8. PubMed ID: 26396494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema.
    Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
    Ophthalmol Retina; 2018 May; 2(5):428-440. PubMed ID: 31047323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.
    Liu Y; Cheng J; Gao Y; Qin L; Min X; Zhang M
    Ann Transl Med; 2020 Mar; 8(6):382. PubMed ID: 32355826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.
    Xiao K; Li FZ; Liang SZ; Wang J; Qian C; Wan GM
    Ann Pharmacother; 2020 Aug; 54(8):750-756. PubMed ID: 32005079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.